Year: 2024

Travere Therapeutics Reports Third Quarter 2024 Financial Results

Written by Customer Service on October 31, 2024. Posted in Earnings Releases And Operating Results.

FILSPARI® (sparsentan) received full FDA approval as the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN Type C meeting scheduled with FDA to discuss potential sNDA submission for FILSPARI in FSGS sNDA requesting modification of liver monitoring for FILSPARI submitted to FDA Net product sales of FILSPARI totaled $35.6 million for the third quarter of 2024; 505 new PSFs received in the period Total revenue for the third quarter of 2024 was $62.9 million, including net product sales of $61.0 million SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc., (NASDAQ: TVTX) today reported its third quarter 2024 financial results and provided a corporate update. “Our performance in the third quarter was exceptional. FILSPARI received full approval as the only medicine that...

Cipher Mining Provides Third Quarter 2024 Business Update

Written by Customer Service on October 31, 2024. Posted in Earnings Releases And Operating Results.

Completed acquisition of Barber Lake data center site, which includes 250 acres of land in West Texas, a newly constructed high-to-mid voltage substation, approvals for 300 MW, and agreements necessary to participate in the ERCOT market Completed acquisition of Reveille data center site, which includes approvals for 70 MW and potential to expand to 200 MW, with energization targeted for 2027 Signed option agreements to purchase or lease three sites in Texas with targeted power capacity of 500 MW each, suitable for HPC or bitcoin mining Third Quarter 2024 Net Loss of $87m, and Adjusted Loss of $3m NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) — Cipher Mining Inc. (NASDAQ: CIFR) (“Cipher” or the “Company”) today announced results for its third quarter ended September 30, 2024, with an update on its operations and business strategy. “We...

Aduro Clean Technologies Reports Fiscal 2025 First Quarter Results

Written by Customer Service on October 31, 2024. Posted in Earnings Releases And Operating Results.

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES LONDON, Ontario, Oct. 31, 2024 (GLOBE NEWSWIRE) — Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (CSE: ACT) (OTCQX: ACTHF) (FSE: 9D5), a clean technology company using the power of chemistry to transform lower value feedstocks, like waste plastics, heavy bitumen, and renewable oils, into resources for the 21st century, has filed its interim consolidated financial results for the three months ended August 31, 2024, and has provided the following highlights. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated. Ofer Vicus, CEO of Aduro, remarked, “This quarter, Aduro continued to achieve essential milestones that underscore our technical progress towards higher market...

Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates

Written by Customer Service on October 31, 2024. Posted in Earnings Releases And Operating Results.

Third-quarter 2024 net sales of $62.2 million Rezdiffra™ (resmetirom) coverage goal achieved early, with more than 80 percent of commercial lives covered; less than 5 percent of Rezdiffra-covered lives require biopsy Completed enrollment of clinical outcomes study of Rezdiffra in patients with compensated NASH/MASH cirrhosis Reports cash, cash equivalents, restricted cash and marketable securities of $1.0 billion at September 30, 2024 Company to host conference call today, October 31, 2024, at 8 a.m. EDTCONSHOHOCKEN, Pa., Oct. 31, 2024 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today reports third-quarter 2024 financial results and...

Malibu Boats, Inc. Announces First Quarter Fiscal 2025 Results

Written by Customer Service on October 31, 2024. Posted in Earnings Releases And Operating Results.

LOUDON, Tenn., Oct. 31, 2024 (GLOBE NEWSWIRE) — Malibu Boats, Inc. (Nasdaq: MBUU) today announced its financial results for the first quarter ended September 30, 2024. First Quarter Fiscal 2025 Highlights Compared to First Quarter Fiscal 2024:Net sales decreased 32.9% to $171.6 million Unit volume decreased 39.7% to 1,024 units Gross profit decreased 50.3% to $28.2 million GAAP net income decreased 124.8% to a net loss of $5.1 million GAAP net income available to Class A Common Stock per share (diluted) decreased 125.5% to a net loss of $0.25 per share Adjusted EBITDA decreased 74.6% to $9.9 million Adjusted fully distributed net income per share decreased 92.9% to $0.08 per share on a fully distributed weighted-average share count of 20.6 million shares of Class A Common Stock“During the first fiscal quarter, we continued...

C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Written by Customer Service on October 31, 2024. Posted in Earnings Releases And Operating Results.

Cemsidomide Phase 1/2 Trial in Multiple Myeloma and non-Hodgkin’s Lymphoma Continues to Progress: Data from Both Indications to be Presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, CA Initial Monotherapy CFT1946 Phase 1 Data Demonstrated Well-Tolerated Safety Profile and Early Evidence of Anti-tumor Activity; Phase 1/2 Trial Continues to Progress with Multiple Data Readouts Expected in 2025 Appointed Paige Mahaney, Ph.D. as Chief Scientific Officer Bringing More than 25 Years of Pharmaceutical and Biotech Experience Cash, Cash Equivalents and Marketable Securities of $284.4 million as of September 30, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to...

Teva Statement on European Commission Decision; Company to Appeal

Written by Customer Service on October 31, 2024. Posted in Public Companies.

Teva Pharmaceuticals disagrees with the European Commission decision, which is based on legal theories that the company believes are extreme, untested, and factually unsupported The company intends to appeal the outcome and is fully prepared to mount its defense Teva has supported the MS community since 1996 and will not be distracted from providing access to this important standard-of-care treatment Teva works to the highest ethical standards with all our external experts and do so in a highly regulated environmentTEL AVIV, Israel, Oct. 31, 2024 (GLOBE NEWSWIRE) — Teva Pharmaceuticals Industries Ltd. (NYSE: and TASE: TEVA) is responding to the European Decision following its investigation into the company’s practices regarding COPAXONE® — the standard-of-care treatment for multiple sclerosis – and announcing its intention...

Notice of Knight Therapeutics’ Third Quarter 2024 Results Conference Call

Written by Customer Service on October 31, 2024. Posted in Public Companies.

MONTREAL, Oct. 31, 2024 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2024 financial results on Thursday, November 7, 2024, prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call. Date: Thursday, November 7, 2024Time: 8:30 a.m. ETTelephone: Toll Free: 1-800-836-8184 or International 1-289-819-1350 Webcast: www.knighttx.com or WebcastThis is a listen-only audio webcast. Media Player is required to listen to the broadcast.Replay: An archived replay will be available for 30 days at www.knighttx.com. About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a...

Nephros Schedules Third Quarter 2024 Financial Results Conference Call

Written by Customer Service on October 31, 2024. Posted in Public Companies.

SOUTH ORANGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) — Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions for both healthcare and commercial markets, today announced that it will file its third-quarter financial results on Thursday, November 7, 2024 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternatively, a replay of the call may be accessed until November 14, 2024 at 1 (877) 344-7529 or 1 (412) 317-0088 for international callers and entering replay access...

Angus Gold Commences Fall Drilling Program on Dorset Gold Zone, Golden Sky Project, Wawa

Written by Customer Service on October 31, 2024. Posted in Public Companies.

TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) — Angus Gold Inc. (TSX-V: GUS | OTC: ANGVF) (“Angus” or the “Company”) is pleased to announce it has commenced the Fall drilling program on its 100%-owned Golden Sky Project located in Wawa, Ontario. Drilling will target the western extension of the Dorset Gold Zone, where Angus has successfully intersected a new zone of high-grade gold, including 7.0 g/t Au over 12.4 metres in Hole GS-24-136, approximately 500 metres to the west of the historical Dorset resource (see News Release of May 7, 2024). Highlights:Complete 2,000m along the western extension of the Dorset Gold Zone following up on the highly prospective drill results from the 2024 drill program including 7.0 g/t Au over 12.4 metres in GS-24-136. All results from the Summer 2024 drilling program at BIF and Dorset are in the final...

Year: 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals